W hy some patients develop limb-and life-saving collaterals but others do not constitutes one of the great challenges that face patients with peripheral vascular and coronary artery disease. A longstanding goal in vascular disease is the establishment of therapies that enhance angiogenesis in compromised tissue beds. To achieve this goal, however, it is essential to define and understand the underlying mechanisms that control angiogenesis and may distinguish individual patient capacity for collateral formation. In this issue of Circulation, Rao and colleagues 1 report that ischemic injury increases DNA methylation in several genes critical for angiogenesis. The methyl-CpG-binding domain 2 (MBD2) protein senses DNA methylation and mediates transcriptional repression of genes involved in angiogenesis and endothelial cell survival. This seminal report mechanistically links epigenetic changes in vascular cells to angiogenesis, paving the way for new therapies that could improve perfusion in patients with vascular disease.
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In mammals, cytosine methylation (5-methylcytosine) is a common epigenetic modification, occurring primarily in regions of DNA where a cytosine nucleotide is adjacent to a guanine nucleotide (so-called CpG sites). Up to 5% of cytosines are methylated, and nearly 60% of genes have CpG-rich islands in their 5Ј regions. 2 During embryonic development, DNA methylation dramatically declines by Ϸ30% in mice. 3 Somatic cells and cancer cells also exhibit alterations in DNA methylation based on environmental stimuli. Because CG dinucleotides base pair to GC, methylation in 1 strand is mirrored by methylation in the other. During replication, methylation in the parent strand targets newly replicated DNA for methylation by recruiting DNA methyltransferases (DNMTs). In this way, stable transfer of gene methylation patterns to progeny lines is accomplished. 4 DNA methylation is often present in organisms with genomes larger than 5ϫ10 8 bp. 5 CpG methylation is thought to constrain expansive regions of the genome by silencing repetitive sequences or repressing promoters. 5 Although methylation is associated with repressed promoters, transcriptional repression via histone methylation and acetylation precedes DNA methylation. 6 Transcriptionally repressed chromatin is targeted by DNMTs, which "permanently" silence genes, enabling the repressive mark to be transmitted to progeny cells. [7] [8] [9] Notably, targeted suppression of transcription enables a nearly 1 million-fold dynamic range for gene expression, a level of plasticity that allows the rich variability that distinguishes various cell types. Thus, DNA methylation is critical for genomic imprinting, X chromosome inactivation in females, and transcriptional repression of transposons. 6, 10 In support of the notion that methylation is a repressive mark, reversal of DNA methylation with the demethylating agent 5-azadeoxycytidine activates gene expression on previously inactivated X chromosomes. 11 The methylation of DNA is afforded by a family of DNA methyltransferases (DNMT1, DNMT3A, and DNMT3B), and cells deficient in these enzymes exhibit decreased chromatin methylation. In mice, deletion of DNMT3B reduces methylation of CpG islands on certain repetitive sequences and activates gene expression on inactive X chromosomes. [12] [13] [14] Similar declines in methylation have been reported in mice deficient for DNMT1. 8, 15, 16 Once DNA methylation is established, methylated DNA is recognized by proteins that specifically bind to the methylated DNA. Over the past 2 decades, members of the methyl-CpG-binding proteins have been identified that possess the capacity for specific CpG binding. Most of the members of this family are related to the methyl binding domain (MBD) of MeCP2 17, 18 and consequently are named MBD1, MBD2, MBD3, and MBD4. The MBD2 isoform binds DNA in a methylation-dependent manner, 19 exhibits particularly strong binding to methylated CpG sites, and represses transcription by recruiting histone deacetylases. 20 Mice lacking MBD2 have no discernable phenotype and exhibit normal genomic methylation. 21 Although the enzymes that methylate DNA and the proteins that bind to methylated DNA have been established, mammalian mechanisms of chomatin demethylation are less well defined.
In endothelial cells, the methylation of the endothelial nitric oxide synthase (eNOS) promoter inversely correlates with its transcriptional activity, 22 and eNOS expression is known to be sensitive to epigenetic mechanisms. 23 In this issue of Circulation, Rao and colleagues 1 extend this knowledge to the physiological setting of angiogenesis and report that genes involved in angiogenesis appear to be tonically regulated by their methylation status via MBD2 binding. After hind-limb ischemia in mice, Rao and coworkers discovered that MBD2 protein levels increase after injury, peak at day 4, and then return to normal by day 14. This expression of MBD2 protein was localized predominantly to the endothelium. To evaluate the significance of the increase in MBD2, Rao et al silenced MBD2 in endothelial cells and observed increased angiogenesis manifest as tube formation in Matrigel. Mice deficient for MBD2 were subjected to hind-limb ischemia and found to have increased angiogenesis and arteriole formation. Even though blood flow proved nearly undetectable in both groups immediately after injury, by day 14, blood flow returned to normal in MBD2-deficient mice, whereas it was only 60% in the control mice. These observations, combined with increased numbers of capillaries and arterioles in the MBD2-deficient mice, established that MBD2 regulates endothelial angiogenic capacity.
In terms of mechanism, Rao and colleagues found that the promoter regions for both vascular endothelial growth factor (VEGF) receptor 2 (VEGF-R2) and eNOS, 2 genes critical for angiogenesis, contained methylated CpG sites that afforded MBD2-mediated suppression of promoter activity. Moreover, these sites underwent increased methylation with ischemia, providing a mechanism for MBD2-mediated promoter suppression with ischemia. Thus, it appears that in the setting of hypoxia or nutrient deprivation, the VEGF-R2/ eNOS axis is "restrained" by MBD2 binding to CpG sites. Thus, by removing MBD2, the actions of VEGF-R2 and eNOS are accentuated and angiogenesis is enhanced. The critical role of eNOS in this response was confirmed by observations that N G -nitro-L-arginine methyl ester, an eNOS inhibitor, abrogated any promotion of angiogenesis in MBD2-null mice.
The results of Rao and colleagues provide a new twist to a body of literature indicating that eNOS is important in the revascularization response to ischemia. Tissue ischemia upregulates both VEGF and VEGF-R2 expression, and this ligand/receptor pair is the major pathway responsible for angiogenesis by inducing the proliferation, sprouting, migration, and permeability of endothelial cells. 24 The binding of VEGF to VEGF-R2 also leads to eNOS activation, which promotes angiogenesis, in part, via enhanced vasodilatation and vascular permeability. 25 The fact that Rao and colleagues found increased levels of eNOS and VEGF-R2 in MBD2-null mice suggests that these 2 molecular targets are rate limiting for the process of ischemic revascularization in wild-type animals. These findings fit well with human studies in which patients with advanced vascular disease often respond poorly to proangiogenic agents, in part, because they typically have significant endothelial dysfunction and poor eNOS-mediated responses. 26 Thus, the results of Rao et al have important therapeutic implications in that they suggest that pharmacological inhibition of MBD2 function is a potential means of enhancing angiogenesis by enhancing eNOS responses. Whether this strategy will work in more complex models of arterial disease such as hypercholesterolemia or diabetes mellitus remains to be established.
Despite the important advances provided by the work of Rao and colleagues, important questions remain. The most obvious pertains to the actual reason for MBD2-mediated constraint of the angiogenic program. It is clear that MBD2 is not critical for developmental angiogenesis because MBD2null mice develop normally. Presumably then, one function of MBD2 is to prevent unabated and chaotic angiogenesis in the setting of tissue ischemia. However, the precise mechanisms of MBD2 regulation in ischemia are not yet clear and, once defined, may present additional therapeutic opportunities. It will also be important to see whether MBD2 expression or DNA binding explains the insufficient tissue perfusion and collateral development (eg, limb ischemia) characteristic of some patient populations such as smokers and diabetics. Finally, even if we develop a means to pharmacologically block MBD2 action, we must be cognizant of the potential consequences. Presumably, cells have evolved this "braking system" to restrain unchecked angiogenesis. Thus, blockade of MBD2 action could induce unrestrained angiogenesis at unwanted sites like the retina, brain, or lung. Although we still lack the answers to many of these basic questions, this new report provides valuable new insights into the epigenetic control of pathways that regulate angiogenesis.
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